Sandbox g28: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
 
(11 intermediate revisions by the same user not shown)
Line 15: Line 15:


:* Empiric antimicrobial therapy
:* Empiric antimicrobial therapy
:: Note (1): The choice of antimicrobial agent should be based on Gram stain results and directed against the likely causative microorganisms in the specific clinical setting.
:: Note (2): Metronidazole is recommended if anaerobes are suspected.  Metronidazole is not necessary for antianaerobic activity if Meropenem is used.
:: Note (3): For coverage of aerobic Gram-negative bacilli, empiric therapy with Cefepime, Ceftazidime, or Meropenem is appropriate.
:: Note (4): Depending on the clinical response, parenteral antimicrobial therapy should be administered for 3 to 4 weeks after drainage.  Parenteral or oral therapy is frequently continued for up to a total of 6 weeks of therapy.
:: Note (5): A longer course of treatment (minimum of 6–8 weeks) may be required if the patient has accompanying osteomyelitis.
:: Note (6): Consider adjunctive medications including prophylactic anticonvulsants, corticosteroids, and mannitol if clinically indicated.
::* '''Intracranial subdural empyema with unclear source of infection'''
::* '''Intracranial subdural empyema with unclear source of infection'''
:::* Preferred regimen: ([[Nafcillin]] 2 g IV q4h or [[Oxacillin]] 2 g IV q4h) {{and}} ([[Ceftriaxone]] or [[Cefotaxime]]) {{and}} [[Metronidazole]]
:::* Preferred regimen: ([[Nafcillin]] 2 g IV q4h or [[Oxacillin]] 2 g IV q4h) {{and}} ([[Ceftriaxone]] 2 g IV q12h or [[Cefotaxime]] 8–12 g/day IV q4–6h) {{and}} [[Metronidazole]] 7.5 mg/kg IV q6h
:::: Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
:::: Note: [[Vancomycin]] should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.


::* '''Intracranial subdural empyema associated with sinusitis or otitis media'''
::* '''Intracranial subdural empyema associated with sinusitis or otitis media'''
:::* Preferred regimen: ([[Nafcillin]] or [[Oxacillin]]) {{and}} ([[Ceftriaxone]] or [[Cefotaxime]]) {{and}} [[Metronidazole]]
:::* Preferred regimen: ([[Nafcillin]] 2 g IV q4h or [[Oxacillin]] 2 g IV q4h) {{and}} ([[Ceftriaxone]] 2 g IV q12h or [[Cefotaxime]] 8–12 g/day IV q4–6h) {{and}} [[Metronidazole]] 7.5 mg/kg IV q6h
:::: Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
:::: Note: [[Vancomycin]] should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
 
::* '''Intracranial subdural empyema after cranial trauma'''
:::* Preferred regimen: [[Nafcillin]] 2 g IV q4h or [[Oxacillin]] 2 g IV q4h
:::: Note: [[Vancomycin]] should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
 
::* '''Intracranial subdural empyema after neurosurgical procedures'''
:::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{and}} [[Ceftazidime]] 2 g IV q8h
 
::* '''Intracranial subdural empyema in neonates (usually associated with meningitis)'''
:::* '''Infants < 1 month'''
::::* Preferred regimen: [[Ampicillin]] 200 mg/kg/day IV q4h {{and}} [[Cefotaxime]] 200 mg/kg/day IV q6h
 
:::* '''Infants 1–3 months'''
::::* Preferred regimen: [[Ampicillin]] 200 mg/kg/day IV q4h {{and}} ([[Cefotaxime]] 200 mg/kg/day IV q6h {{or}} [[Ceftriaxone]] 100 mg/kg/day IV q12h)


:::* '''Infants > 3 months'''
::::* Preferred regimen: [[Vancomycin]] 60 mg/kg/day IV q6h {{and}} ([[Cefotaxime]] 200 mg/kg/day IV q6h {{or}} [[Ceftriaxone]] 100 mg/kg/day IV q12h {{or}} [[Cefepime]] 150 mg/kg/day IV q8h)


::* '''Spinal subdural empyema'''
:::* Preferred regimen: [[Nafcillin]] 2 g IV q4h or [[Oxacillin]] 2 g IV q4h
:::: Note: [[Vancomycin]] should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.


:::: Note (1): The choice of antimicrobial agent should be based on Gram stain results and the likely causative microorganisms.
:::: Note (2): Metronidazole is recommended if anaerobes are suspected.  Metronidazole is not necessary for antianaerobic activity if Meropenem is used.
:::: Note (3): For coverage of aerobic Gram-negative bacilli, empiric therapy with Cefepime, Ceftazidime, or Meropenem is appropriate.
:::: Note (4): Depending on the clinical response, parenteral antimicrobial therapy should be administered for 3 to 4 weeks after drainage.  Parenteral or oral therapy is frequently continued for up to a total of 6 weeks of therapy.
:::: Note (5): A longer course of treatment (minimum of 6–8 weeks) may be required if the patient has accompanying osteomyelitis.
:::: Note (6): Consider adjunctive medications including prophylactic anticonvulsants, corticosteroids, and mannitol if clinically indicated.
:* Pathogen-directed antimicrobial therapy
:* Pathogen-directed antimicrobial therapy
::* '''Staphylococcus aureus, methicillin-resistant (MRSA)'''
::* '''Staphylococcus aureus, methicillin-resistant (MRSA)'''

Latest revision as of 04:59, 8 June 2015

Subdural empyema ⇧ Return to Top ⇧
  • Causative pathogens
  • More common
  • Streptococcus milleri
  • Other streptococci and enterococci
  • Aerobic Gram-negative bacilli (Haemophilus influenzae, Proteus, Escherichia coli, Pseudomonas, Klebsiella, Acinetobacter, Salmonella, Morganella, Eikenella)
  • No growth
  • Less common
  • Streptococcus pneumoniae
  • Staphylococcus aureus, coagulase-negative staphylococci
  • Anaerobic Gram-positive cocci (Veillonella, Peptostreptococcus, others)
  • Anaerobic Gram-negative bacilli (Bacteroides, Fusobacterium, Prevotella)
  • Empiric antimicrobial therapy
Note (1): The choice of antimicrobial agent should be based on Gram stain results and directed against the likely causative microorganisms in the specific clinical setting.
Note (2): Metronidazole is recommended if anaerobes are suspected. Metronidazole is not necessary for antianaerobic activity if Meropenem is used.
Note (3): For coverage of aerobic Gram-negative bacilli, empiric therapy with Cefepime, Ceftazidime, or Meropenem is appropriate.
Note (4): Depending on the clinical response, parenteral antimicrobial therapy should be administered for 3 to 4 weeks after drainage. Parenteral or oral therapy is frequently continued for up to a total of 6 weeks of therapy.
Note (5): A longer course of treatment (minimum of 6–8 weeks) may be required if the patient has accompanying osteomyelitis.
Note (6): Consider adjunctive medications including prophylactic anticonvulsants, corticosteroids, and mannitol if clinically indicated.
  • Intracranial subdural empyema with unclear source of infection
Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
  • Intracranial subdural empyema associated with sinusitis or otitis media
Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
  • Intracranial subdural empyema after cranial trauma
Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
  • Intracranial subdural empyema after neurosurgical procedures
  • Intracranial subdural empyema in neonates (usually associated with meningitis)
  • Infants < 1 month
  • Infants 1–3 months
  • Infants > 3 months
  • Spinal subdural empyema
Note: Vancomycin should be used in place of nafcillin or oxacillin if MRSA is suspected or if penicillin allergy is present.
  • Pathogen-directed antimicrobial therapy
  • Staphylococcus aureus, methicillin-resistant (MRSA)
  • Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h for 4–6 weeks
  • Alternative regimen: Linezolid 600 mg PO/IV q12h for 4–6 weeks OR TMP-SMX 5 mg/kg/dose PO/IV q8–12h for 4–6 weeks
  • Pediatric dose: Vancomycin 15 mg/kg/dose IV q6h OR Linezolid 10 mg/kg/dose PO/IV q8h
Note: Consider the addition of Rifampin 600 mg qd or 300–450 mg bid to vancomycin.


  1. Osborn, Melissa K.; Steinberg, James P. (2007-01). "Subdural empyema and other suppurative complications of paranasal sinusitis". The Lancet. Infectious Diseases. 7 (1): 62–67. doi:10.1016/S1473-3099(06)70688-0. ISSN 1473-3099. PMID 17182345. Check date values in: |date= (help)
  2. Greenlee, John E. (2003-01). "Subdural Empyema". Current Treatment Options in Neurology. 5 (1): 13–22. ISSN 1092-8480. PMID 12521560. Check date values in: |date= (help)